Enliven Therapeutics (NASDAQ:ELVN) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a sell rating to a hold rating in a research report released on Monday.

A number of other research analysts have also recently commented on ELVN. HC Wainwright upped their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Mizuho upped their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, The Goldman Sachs Group upped their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.80.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $39.59 on Monday. The business’s 50 day moving average is $37.48 and its two-hundred day moving average is $27.59. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $48.53. The stock has a market capitalization of $2.41 billion, a P/E ratio of -23.71 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director owned 22,647 shares in the company, valued at $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The disclosure for this sale is available in the SEC filing. 25.90% of the stock is owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. HighVista Strategies LLC lifted its holdings in shares of Enliven Therapeutics by 83.1% during the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock valued at $5,304,000 after purchasing an additional 117,619 shares during the last quarter. Candriam S.C.A. lifted its holdings in shares of Enliven Therapeutics by 46.3% during the 3rd quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock valued at $12,473,000 after purchasing an additional 192,702 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at $334,000. Rhumbline Advisers lifted its holdings in shares of Enliven Therapeutics by 19.6% during the 3rd quarter. Rhumbline Advisers now owns 60,160 shares of the company’s stock valued at $1,231,000 after purchasing an additional 9,880 shares during the last quarter. Finally, NEOS Investment Management LLC lifted its holdings in shares of Enliven Therapeutics by 23.7% during the 3rd quarter. NEOS Investment Management LLC now owns 40,314 shares of the company’s stock valued at $825,000 after purchasing an additional 7,735 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.